EVH Stock Cash Flow Statements

Evolent Health Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Evolent Health Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31

cash flows from operating activities
net income before preferred dividends and accretion of series a preferred stock	-19,897,000	-64,618,000	-22,802,000	-23,137,000	1,596,000	-17,280,000
adjustments to reconcile net income to net cash and restricted cash from operating activities:
change in fair value of contingent consideration	3,206,000	-280,000	-4,200,000	200,000	0	8,908,000	5,937,000	11,300,000	-7,822,000	8,569,000	-17,700,000	-12,700,000	800,000	6,078,000
gain from equity method investees	-197,000	19,000	-182,000	2,229,000	1,700,000	-306,000	-28,000	-684,000	-155,000	-423,000	-629,000	-1,392,000	-1,952,000	-596,000
extinguishment of series a preferred stock
loss on option exercise	196,000	52,348,000
depreciation and amortization expenses	23,141,000	24,058,000	29,296,000	29,701,000	29,870,000	29,503,000	29,602,000	32,404,000	32,134,000	29,275,000	19,781,000	17,196,000	15,112,000	15,106,000	14,915,000	14,859,000	14,916,000	15,347,000	14,865,000	14,694,000	15,778,000	16,138,000
stock-based compensation expense	11,580,000	11,081,000	-6,115,000	14,416,000	12,659,000	18,786,000	10,603,000	10,222,000	8,966,000	10,710,000	14,631,000	6,992,000	7,012,000	5,346,000	4,957,000	4,395,000	3,653,000	3,706,000	4,231,000	3,164,000	3,703,000	3,508,000
deferred tax expense	-865,000	295,000
amortization of contract cost assets	1,286,000	1,237,000	1,194,000	1,285,000	1,114,000	1,205,000	2,939,000	2,333,000	3,382,000	2,290,000	8,288,000	1,582,000	1,497,000	11,689,000	3,113,000	1,617,000	5,256,000	3,055,000	5,258,000	5,665,000	4,658,000	5,614,000
amortization of deferred financing costs	1,249,000	1,154,000	897,000	885,000	883,000	882,000	900,000	997,000	1,004,000	911,000	540,000	683,000	540,000	539,000	4,646,000	4,562,000	4,467,000	4,370,000	4,687,000	4,014,000	3,070,000	3,009,000
loss on lease termination	0	1,906,000
change in tax receivables agreement liability			0	0	0	173,000	-4,202,000
right-of-use operating assets	384,000	408,000	522,000	799,000	747,000	1,193,000	5,496,000	9,982,000	-3,473,000	4,620,000	1,669,000	1,500,000	-2,387,000	1,718,000	2,436,000	1,787,000	1,781,000	2,840,000	2,441,000	5,873,000	-3,075,000	6,695,000
other current operating cash inflows (outflows)		2,000	0								449,000	1,471,000	1,049,000	-357,000					935,000	1,585,000	-300,000	524,000
changes in assets and liabilities, net of acquisitions:
accounts receivable, net and contract assets	71,740,000	-15,815,000	-6,782,000	-34,177,000	54,012,000	19,009,000	-52,517,000	-49,040,000	-82,969,000	19,832,000	-68,184,000	-47,838,000	59,341,000	-46,299,000	47,099,000	67,188,000	-56,833,000	-63,233,000	-31,352,000	8,281,000	12,703,000	-36,649,000
prepaid expenses and other current and non-current assets	5,926,000	-7,729,000	-3,241,000	1,816,000	-1,231,000	7,166,000	5,781,000	4,748,000	-7,384,000	-13,758,000	4,082,000	6,044,000	-2,382,000	-6,071,000	5,739,000	3,299,000	-4,476,000	1,037,000
contract cost assets	-456,000	-1,193,000	-1,369,000	-1,068,000	-2,063,000	-1,556,000	-1,644,000	-1,099,000	-1,533,000	-1,326,000	-961,000	-3,448,000	-2,178,000	-1,106,000	-10,540,000	-4,448,000	-2,301,000	-1,690,000	-3,454,000	-2,443,000	-2,177,000	-3,326,000
accounts payable	14,925,000	3,264,000	2,988,000	16,590,000	-6,909,000	-8,421,000	5,905,000	104,000	853,000	-13,585,000	7,229,000	6,759,000	-1,249,000	426,000	-914,000	-1,740,000	509,000	9,395,000	3,941,000	-12,084,000	622,000	11,068,000
accrued liabilities	13,012,000	-18,879,000	-41,846,000	18,138,000	-11,125,000	10,635,000	-3,884,000	15,593,000	7,159,000	4,785,000	-888,000	-3,077,000	-27,046,000	2,220,000	13,569,000	3,832,000	-8,027,000	-9,698,000	2,537,000	2,193,000	4,749,000	-678,000
operating lease liabilities	-18,153,000	-2,820,000	-2,774,000	-1,521,000	-8,106,000	-2,582,000	-4,941,000	-10,094,000	3,912,000	-4,250,000	-1,760,000	-1,402,000	2,171,000	-1,992,000	-1,933,000	-1,870,000	-1,948,000	-771,000	-2,292,000	-2,273,000	7,703,000	-5,920,000
accrued compensation and employee benefits	2,348,000	2,195,000	2,105,000	285,000	2,214,000	-27,279,000	6,755,000	11,836,000	10,758,000	-31,401,000	14,898,000	7,928,000	10,056,000	-32,435,000	16,349,000	8,694,000	6,509,000	-28,014,000	15,793,000	5,468,000	8,025,000	-18,143,000
deferred revenue	-2,684,000	2,510,000	-114,000	-1,937,000	-1,578,000	160,000	-127,000	-1,186,000	-119,000	1,169,000	-1,767,000	-1,508,000	-4,577,000	1,344,000	-3,842,000	613,000	-194,000	2,684,000	1,868,000	-4,411,000	-3,777,000	-2,623,000
reserve for claims and performance-based arrangements	-146,591,000	15,137,000	6,018,000	-4,876,000	-51,076,000	-35,409,000	104,306,000	53,931,000	48,614,000	-2,533,000	64,032,000	9,738,000	-38,278,000	-7,056,000	-20,583,000	-45,830,000	30,113,000	32,501,000	-19,629,000	-49,738,000	5,399,000	27,860,000
other long-term liabilities	518,000	285,000	-263,000	-189,000	-136,000	-65,000	0	-282,000	-200,000	-277,000	-523,000	-326,000	-344,000	-514,000	-3,942,000	-310,000	-407,000	1,925,000	3,758,000	3,935,000	380,000	93,000
net cash and restricted cash from operating activities	-30,334,000	4,565,000	-26,231,000	18,670,000	21,417,000	4,909,000	89,381,000	60,521,000	654,000	-7,974,000	35,695,000	-3,470,000	13,664,000	-57,442,000	66,656,000	44,501,000	-24,247,000	-48,163,000	-12,851,000	-20,499,000	37,666,000	-20,541,000
cash flows used in investing activities
cash paid for asset acquisitions and business combinations	-51,549,000	-4,498,000	-13,778,000	-11,000,000	-4,562,000	-1,385,000	0	0	-1,522,000	-386,724,000	-3,090,000	-235,951,000	-9,000,000	-70,000
return of equity method investments			0	0			0	71,000	13,000	786,000	1,377,000	0	1,800,000	2,375,000	0	4,846,000	0	9,372,000
purchases of investments and contributions to equity method investees			-1,000	-2,440,000
investments in internal-use software and purchases of property and equipment	-8,770,000	-8,595,000	-6,151,000	-6,289,000	-7,106,000	-5,347,000	-6,052,000	-6,793,000	-6,845,000	-9,055,000	-10,743,000	-9,874,000	-9,236,000	-8,508,000	-7,244,000	-6,227,000	-5,571,000	-5,941,000	-5,859,000	-6,159,000	-10,055,000	-7,400,000
net cash and restricted cash from investing activities	-60,531,000	-13,093,000	-19,930,000	-19,729,000	-13,541,000	-9,732,000	-6,052,000	-6,145,000	-8,354,000	-394,993,000	-4,456,000	-254,989,000	-16,436,000	16,766,000	-54,368,000	-1,798,000	-5,571,000	45,951,000	-2,225,000	281,679,000	-7,575,000	-10,807,000
cash flows from financing activities
changes in working capital balances related to claims processing	-3,278,000	-41,476,000	42,953,000	-5,525,000	-31,411,000	37,520,000
payment of contingent consideration			0	0	-66,600,000	-3,755,000
proceeds from stock option exercises			-1,000	2,343,000	61,000	1,058,000	3,336,000	4,529,000	3,073,000	1,581,000		2,971,000	0	309,000			2,858,000	6,518,000			442,000	84,000
proceeds from issuance of long-term debt, net of offering costs	0	221,000,000	59,105,000	0	0	-529,000	391,431,000	0	-267,000	256,330,000
repayment of long-term debt	0	-62,500,000					-416,701,000	-10,000,000	0	-37,500,000
payment of preferred dividends	-4,621,000	-4,577,000	-4,806,000	-5,134,000	-5,067,000	-5,078,000	-5,162,000	-5,096,000	-4,884,000	-3,651,000
taxes withheld and paid for vesting of equity awards	-28,000	-4,593,000	-309,000	-692,000	-364,000	-14,334,000	-944,000	-1,603,000	-138,000	-12,607,000		-948,000	-257,000	-16,214,000
net cash and restricted cash from financing activities	-8,927,000	107,854,000	96,942,000	-9,008,000	-103,381,000	14,882,000	-84,352,000	-37,367,000	23,330,000	379,729,000		173,081,000	20,690,000	-51,376,000			-35,503,000	-55,584,000
effect of exchange rate on cash and cash equivalents and restricted cash	-83,000	23,000	-136,000	-31,000	-24,000	-38,000	-18,000	-110,000	-1,000	50,000		-237,000	-271,000	-104,000			-55,000	1,000			-15,000	41,000
net increase in cash and cash equivalents and restricted cash		99,349,000	50,645,000			10,021,000	-1,041,000										-65,376,000	-57,795,000
loss on disposal of non-strategic assets
loss on discontinued operations
deferred tax benefit			-1,073,000				-15,058,000				777,000				-238,000	-20,000	-209,000	-59,000	-359,000	119,000	-950,000	58,000
loss on extinguishment/repayment of debt											0
right-of-use asset impairment							0	0
proceeds from transfer of membership and release of passport escrow											8,000,000	0	0	22,969,000	0	0	0	42,996,000
disposal of non-strategic assets and divestiture of discontinued operations							0				0				0	0	0	3,490,000
distributions to sponsors												0	-13,784,000	-1,100,000
proceeds from issuance of preferred stock, net of offering costs							0	0	0	168,000,000
cash and cash equivalents and restricted cash as of beginning-of-period			0				0	0	0	215,158,000		0	0	354,942,000			17,000	361,564,000
cash and cash equivalents and restricted cash as of end-of-period			50,645,000				-1,041,000	16,899,000	15,629,000	191,970,000		-85,615,000	17,647,000	262,786,000			-65,359,000	303,769,000
deferred tax provision					-1,160,000	181,000			-2,291,000	-68,728,000			604,000	-132,000
other current operating cash outflows					6,000	6,000	-51,000	-140,000	76,000	-56,000						1,443,000	-663,000	-66,000
net decrease in cash and cash equivalents and restricted cash									15,629,000	-23,188,000		-85,615,000	17,647,000	-92,156,000
purchases of investments						-3,000,000									-1,000	0	0	-2,994,000	-2,000	-9,721,000	-109,000	-1,338,000
net income before dividends declared and accretion of series a preferred stock							-33,411,000	-25,324,000	-34,323,000	-19,982,000
gain on transfer of membership															-22,969,000	0	0	-22,969,000
maturities and sales of investments															0	0	0	500,000	2,536,000			618,000
changes in working capital balances related to claims processing on behalf of partners							-9,439,000	-25,197,000	25,546,000	7,576,000		-48,682,000	34,731,000	-34,371,000	60,057,000	-1,294,000	-36,606,000	39,005,000	-3,832,000	-28,927,000	-6,963,000	33,678,000
repayment and repurchase of 2021 notes and financing fees
loss on disposal of assets																						6,447,000
cash flows used in operating activities
change in tax receivable agreement liability									0	66,184,000	3,080,000
cash flows from investing activities
net income											-11,349,000	2,123,000	-4,588,000	-5,350,000	-5,647,000	-13,040,000	-9,107,000	-9,807,000	-13,803,000	-38,170,000	-203,521,000	-78,752,000
impairment of equity method investees
goodwill impairment																			0	0
loan for implementation funding																				0	0	-400,000
impact to cash and cash equivalents and restricted cash from initial consolidation
other investing activities
gain on discontinued operations												0
repayment of credit agreement including settlement of warrants
proceeds from issuance of long term debt, net of offering costs
loss on repayment of debt															2,185,000	0	0	19,158,000
cash flows used in financing activities
unrealized loss on investments
repayment and termination of credit agreement including settlement of warrants
change in fair value of contingent consideration and indemnification asset															14,100,000	-225,000	0	-594,000	4,352,000	2,570,000	756,000	-3,818,000
(gain) loss on disposal of assets															8,690,000	0	0	-1,904,000
(gain) income from equity method investees															-454,000	-63,000	-4,879,000	-7,783,000	975,000
impairment of equity method investments
interest from customer advance for regulatory capital requirements															-81,000				-81,000	-472,000	-666,000	-650,000
customer advance for regulatory capital requirements
investments in equity method investees
amount received from escrow in asset acquisition
issuance of warrant liability
taxes withheld and paid for vesting of restricted stock units																	-455,000	-2,687,000			-143,000	-1,188,000
cash paid for asset acquisitions																-417,000	0	-1,472,000
repayment and termination of credit agreement including settlement of warrants.																0	0	-98,420,000
bad debt expense																		2,407,000
principal repayment of implementation funding loan and regulatory and capital requirements
gain on disposal of assets and consolidation
loss on extinguishment of debt																			0
prepaid expenses and other current and noncurrent assets																			-1,773,000	13,025,000	-5,371,000	1,459,000
cash flows from (used in) investing activities
cash paid for asset acquisitions or business combinations
disposal of non-strategic assets																			0	0	0	-2,287,000
investments in and advances to equity method investees
impact to cash and cash equivalents and restricted cash from initial consolidation of passport
purchase and maturities of restricted investments																			0	-2,000
cash flows from (used in) financing activities
gain on disposal of assets																				0
equity method investments impairment																				0	0	47,133,000
deferred financing costs related to 2025 notes
cash flows from (used in) operating activities
(income) income from equity method investees
maturities of investments
cash flows (used in) from financing activities
income from equity method investees																						412,000
net cash and restricted cash (used in) from financing activities																						32,574,000
investments in and purchases of property and equipment
proceeds from issuance of common stock, net of stock issuance costs
change in warrant liability
proceeds from issuance of long-term debt, net of issuance costs
adjustments to reconcile net income to net cash and restricted cash
provided by operating activities:
non-cash interest income
other
accounts receivables, net and contract assets
reserves for claims and performance-based arrangements
rou operating assets
principal repayment of implementation funding loan and regulatory capital requirements
purchases of restricted investments
maturities of restricted investments
principal repayment of implementation funding loan
income from lease abandonment
acceleration of unvested equity awards for valence health employees
claims reserves
proceeds from issuance of convertible notes, net of issuance costs
accounts receivables
contract assets
principal repayment for implementation funding loan
purchases of property and equipment
purchases and maturities of restricted investments
change in restricted cash held on behalf of partners for claims processing
(income) income from affiliates
impact of lease termination
accretion of bond premium
investments in and advances to affiliates
income from affiliates
contract cost amortization
accretion of bond premium/discounts
amount received from vestica healthcare llc escrow
gain on consolidation
change in fair value of contingent liability
prepaid expenses and other assets
other liabilities
cash acquired upon consolidation of affiliate
cash paid for asset acquisition or business combination
purchase of restricted investments
payments of deferred offering costs
adjustments to reconcile net income to net cash from operating activities:
undistributed losses from affiliates
prepaid expenses and other current assets
accounts payable, net of change in restricted cash and restricted investments
net cash from operating activities
change in restricted cash and restricted investments
net cash from investing activities
net cash from financing activities
net increase in cash and cash equivalents
cash and cash equivalents as of beginning-of-period
cash and cash equivalents as of end-of-period
loss on change in fair value of contingent consideration
taxes withheld for vesting of restricted stock units
gain on change in fair value of contingent liability
acceleration of unvested equity awards for valence employees
other current liabilities
proceeds from initial public offering, net of offering costs
supplemental disclosure of non-cash investing and financing activities
non-cash contribution of common stock to evolent health llc prior to the offering reorganization
non-cash repurchase of series a preferred stock
non-cash issuance of series b-1 preferred stock
non-cash issuance of class a common stock
non-cash deferred financing costs payable
acquisition consideration payable
accrued property and equipment purchases
effects of the offering reorganization
reclassification of deferred offering costs acquired to additional paid-in capital
conversion of existing equity as part of the offering reorganization
issuance of class b common stock
assumption of non-controlling interest as a result of merger with tpg affiliate
effects of the secondary offering
decrease in non-controlling interests as a result of the exchange
changes in assets and liabilities:
change in restricted cash
cash paid in connection with acquisition
stock issued in connection with business combinations
effects of the offering reorganization:
adjustments to reconcile net income to net cash from operating
activities:
gain on deconsolidation
cash transferred upon deconsolidation of affiliate
proceeds from issuance of series b preferred stock
proceeds from issuance of convertible notes
repurchase of series a preferred stock
non-cash settlement of accounts receivable through reacquisition of series a preferred stock
conversion of accrued interest from convertible notes to equity
conversion of convertible notes to equity

We provide you with 20 years of cash flow statements for Evolent Health stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Evolent Health stock. Explore the full financial landscape of Evolent Health stock with our expertly curated income statements.

The information provided in this report about Evolent Health stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.